Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | PRKCI | P41743 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | CCNK | O75909 | 1/20 | 0.30 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737516 | 0.82 | BTK (0.36) | AXLPRKCIBTKJAK3 | |
| SCHEMBL6127940 | 0.81 | AXL (0.42) | AXLPRKCIBTKCCR8CCNK | |
| SCHEMBL18819909 | 0.77 | BTK (0.33) | BTK | |
| SCHEMBL26145364 | 0.77 | AXL (0.44) | AXLPRKCIAHRDYRK1ARHEB | |
| SCHEMBL12491288 | 0.76 | PRKCI (0.42) | AXLPRKCIAHRDYRK1ARHEB | |
| SCHEMBL8736950 | 0.75 | TAAR1 (0.36) | AXLPRKCIBTKCCNKCDK12 | |
| SCHEMBL8735125 | 0.74 | PRKCI (0.42) | AXLPRKCIBTKCCR8CCNK | |
| SCHEMBL20577529 | 0.73 | PRKCI (0.40) | AXLPRKCIAHRDYRK1ARHEB | |
| SCHEMBL31000812 | 0.73 | PRKCI (0.40) | AXLPRKCIAHRDYRK1ARHEB | |
| SCHEMBL18101002 | 0.72 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | AXL 530/4885PRKCI 3753/4885AHR 2160/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | AXL 530/4885PRKCI 3753/4885AHR 2160/4885 |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | AXL 530/4885PRKCI 3753/4885AHR 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.